Ocular Therapeutix (OCUL) shares 2025 full-year and Q4 results via 8-K

Rhea-AI Filing Summary

Ocular Therapeutix, Inc. reported that it has released its financial results for the quarter and year ended December 31, 2025. These results were announced in a press release dated February 5, 2026.

The company furnished the full text of this earnings press release as Exhibit 99.1. This information is provided under a disclosure rule for earnings results and is designated as “furnished,” meaning it is not treated as formally “filed” under certain securities law liability provisions or automatically incorporated into other securities filings unless specifically referenced.

false 0001393434 0001393434 2026-02-05 2026-02-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 5, 2026

OCULAR THERAPEUTIX, INC.

(Exact Name of Company as Specified in Charter)

Delaware		001-36554		20-5560161
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

15 Crosby Drive

Bedford, MA 01730

(Address of Principal Executive Offices) (Zip Code)

Company’s telephone number, including area code: (781) 357-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		OCUL		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company    ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02 Results of Operations and Financial Condition.

On February 5, 2026, Ocular Therapeutix, Inc. announced its financial results for the quarter and year ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

99.1	Press Release of Ocular Therapeutix, Inc., dated February 5, 2026
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	OCULAR THERAPEUTIX, INC.
Date: February 5, 2026	By:	/s/ Jason S. Robins
		Jason S. Robins
		Interim Chief Financial Officer

FAQ

What did Ocular Therapeutix (OCUL) disclose in its latest 8-K filing?

Ocular Therapeutix disclosed that it announced financial results for the quarter and year ended December 31, 2025. The details of those results are contained in a press release dated February 5, 2026, which is furnished as Exhibit 99.1 to the report.

Where can investors find Ocular Therapeutix’s 2025 year-end financial results?

The company’s 2025 year-end and fourth quarter financial results are contained in a press release furnished as Exhibit 99.1. This press release, dated February 5, 2026, accompanies the Form 8-K and is incorporated by reference into the current report.

How are the Ocular Therapeutix (OCUL) earnings materials treated under securities laws?

The earnings information, including Exhibit 99.1, is furnished under the earnings disclosure item and is not deemed “filed” under Section 18 of the Exchange Act. It is also not automatically incorporated into other securities filings unless specifically referenced there.

Which period do the newly announced Ocular Therapeutix results cover?

The announced results cover both the quarter and the full fiscal year ended December 31, 2025. Ocular Therapeutix stated that these financial results are described in a press release dated February 5, 2026, which is attached to the current report as Exhibit 99.1.

Who signed the latest Ocular Therapeutix (OCUL) Form 8-K?

The Form 8-K was signed on behalf of Ocular Therapeutix, Inc. by Jason S. Robins. He is identified in the report as the company’s Interim Chief Financial Officer and executed the filing dated February 5, 2026.

What exhibits are included with the Ocular Therapeutix February 5, 2026 8-K?

The filing includes Exhibit 99.1, which is a press release dated February 5, 2026 detailing financial results, and Exhibit 104, which is the cover page interactive data file embedded within the Inline XBRL document associated with the current report.